Clinical Research Papers:
Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer
Metrics: PDF 671 views | HTML 896 views | ?
Bao-tian Huang1, Zhu Lin1, Pei-xian Lin2, Jia-yang Lu1, Chuang-zhen Chen1
1Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China
2Department of Nosocomial Infection Management, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China
Chuang-zhen Chen, e-mail: email@example.com
Jia-yang Lu, e-mail: firstname.lastname@example.org
Keywords: radiobiological modeling, dose schedule, stereotactic body radiotherapy, non-small cell lung cancer
Received: December 11, 2015 Accepted: April 18, 2016 Published: May 18, 2016
This study aims to compare the radiobiological response of two stereotactic body radiotherapy (SBRT) schedules for patients with stage I peripheral non-small cell lung cancer (NSCLC) using radiobiological modeling methods. Volumetric modulated arc therapy (VMAT)-based SBRT plans were designed using two dose schedules of 1 × 34 Gy (34 Gy in 1 fraction) and 4 × 12 Gy (48 Gy in 4 fractions) for 19 patients diagnosed with primary stage I NSCLC. Dose to the gross target volume (GTV), planning target volume (PTV), lung and chest wall (CW) were converted to biologically equivalent dose in 2 Gy fraction (EQD2) for comparison. Five different radiobiological models were employed to predict the tumor control probability (TCP) value. Three additional models were utilized to estimate the normal tissue complication probability (NTCP) value for the lung and the modified equivalent uniform dose (mEUD) value to the CW. Our result indicates that the 1 × 34 Gy dose schedule provided a higher EQD2 dose to the tumor, lung and CW. Radiobiological modeling revealed that the TCP value for the tumor, NTCP value for the lung and mEUD value for the CW were 7.4% (in absolute value), 7.2% (in absolute value) and 71.8% (in relative value) higher on average, respectively, using the 1 × 34 Gy dose schedule.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.